PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders

(a)On June30, 2017, the Company held its Annual Meeting. Of the 43,058,827 shares of Common Stock issued and outstanding and eligible to vote as of the record date of May8, 2017, a quorum of 28,580,484 shares, or 66.37% of the outstanding shares, were present in person or by proxy.

(b)The following actions were taken at the Annual Meeting:

1. The following nominees were reelected to serve on the Company’s Board of Directors as Class III Directors until the Company’s 2020 annual meeting of stockholders, based on the following votes:

2. The selection of Ernst& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2016 was ratified, based on the following votes:

About PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.